摘要
随着分子生物学的进展,针对HCV生活周期中病毒蛋白靶向特异性治疗的许多小分子化合物的研究得到了迅速发展,提高了抗病毒疗效。这些药物统一命名为直接作用抗病毒药物(directly acting antivirals,DAAs),包括非结构蛋白(nonstructural,NS)3/4A蛋白酶抑制剂、NS5B聚合酶抑制剂和NS5A蛋白抑制剂等。2011年以来,以上三类药物中的多种药物已陆续在美国和欧洲上市,在临床试验和实践中取得了比较好的疗效。本文对已上市DAAs的临床应用方案、适用人群及疗效进行简要阐述,并介绍DAAs治疗在特殊人群中的应用进展。
Recent advances in molecular biology have led to a large number of new therapies with small molecule direct antivirals developed for chronic hepatitis C to enhance the antiviral therapeutic efficacy, which target specific HCV enzymes in HCV life cycle. These drugs, collectively termed as direct-acting antiviral agents（DAAs） against HCV, include a range of non-structural（NS） 3/NS4 A protease, NS5 B polymerase, and NS5 A inhibitors at various stages of clinical development. Since 2011, these three categories of drugs have been approved successively in the United States and Europe, and good efficacy has been achieved both in clinical trials and clinical practice. This review summarizes the clinical application of DAAs, suitable population and the efficacy, and introduces the progress of clinical application of DAAs in special HCV populations.
出处
《传染病信息》
2015年第5期266-269,共4页
Infectious Disease Information
